Stocks Movement Analysis: Juno Therapeutics Inc. (NASDAQ:JUNO), Opko Health, Inc. (NASDAQ:OPK)

Juno Therapeutics Inc. (NASDAQ:JUNO)

The company announced its last quarter financial performance results on 11/09/2016. Juno Therapeutics Inc. (NASDAQ:JUNO) belongs to Medical sector that declined -3.87% in value when last trading session closed at $22.12. The company has a market capitalization of $2.34 Billion. The company’s stock has a Return on Assets (ROA) of -19 percent, a Return on Equity (ROE) of -24 percent and Return on Investment (ROI) of -20.3 percent. The company reached its 52-Week high of $57.82 on Dec 1, 2015 and 52-Week low of $19.41 on Nov 23, 2016.

Earnings per share (ttm) for Juno Therapeutics Inc. (NASDAQ:JUNO) according to Finviz Data is $-2.81.

This company was Downgrade by SunTrust on 25-Nov-16  to Hold.

The 12 analysts offering 12-month price forecasts for Juno Therapeutics Inc have a median target of 45.00, with a high estimate of 61.00 and a low estimate of 23.00. The median estimate represents a +103.44% increase from the last price of 22.12.

Financial History:

Following Earnings result, share price were UP 4 times out of last 7 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 25% percent of times. It has met expectations  2  times and missed earnings  4  times.

The consensus recommendation for Juno Therapeutics Inc. (NASDAQ:JUNO) is 2.3. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 1.78. In comparison, the consensus recommendation 60 days ago was at 1.63, and 90 days ago was at 1.63 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects Juno Therapeutics Inc. to have earnings per share of $-0.62.

Revenue is expected to range from 7.5 Million to 20.3 Million with an average of 13.96 Million.

Company Profile:

Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.

Opko Health, Inc. (NASDAQ:OPK):

Opko Health, Inc. (NASDAQ:OPK) belongs to Medical sector closed its last session with a loss of -1.85 percent and closed its previous trading session at $10.62. According to Finviz reported data, the stock currently has Earnings per Share (EPS) (ttm) of $-0.02. The company has the Market capitalization of $5.92 Billion. The company’s stock has a Return on Assets (ROA) of -0.4 percent, a Return on Equity (ROE) of -0.5 percent and Return on Investment (ROI) of 0.7 percent. The company reached its 52-Week high of $11.85 on Mar 22, 2016 and 52-Week low of $7.12 on Jan 20, 2016.

This company was Initiated by Standpoint Research on 3-Jun-16 to Buy.

The 5 analysts offering 12-month price forecasts for OPKO Health Inc have a median target of 15.00, with a high estimate of 22.00 and a low estimate of 10.00. The median estimate represents a +41.24% increase from the last price of 10.62.

Financial History:

Following Earnings result, share price were UP 13 times out of last 26 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 75% percent of times. It has met expectations  1 times and missed earnings  2  times.

The consensus recommendation for Opko Health, Inc. (NASDAQ:OPK) is 1.5. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 1.5. In comparison, the consensus recommendation 60 days ago was at 2, and 90 days ago was at 2 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects Opko Health, Inc. to have earnings per share of $-0.05.

Revenue is expected to range from 303.9 Million to 320.2 Million with an average of 312.63 Million.

Company Profile:

OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.